Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Physiomics ( (GB:PYC) ) has provided an announcement.
Physiomics reported record first-half total income of £528,000 for the six months to 31 December 2025, up 51% year-on-year and its highest half-year income since inception, driven by expanded Modelling and Simulation work and a new Biometrics service line. Revenue rose to £498,000 but operating losses widened to £327,000 due to hiring and temporary reliance on external contractors, while cash stood at £257,000 and shareholders’ funds at £393,000.
The company launched its Biometrics service line, hired a new Head of Biometrics and a senior quantitative pharmacology scientist, and secured 11 new contracts, including deals with longstanding client Numab Therapeutics and global health organisation GARDP. Management expects full-year 2026 income to meet market forecasts for a 27% increase versus 2025 and anticipates a 24% reduction in loss after tax, supported by better utilisation of internal staff, reduced use of external consultants, and a robust pipeline extending into 2027 including new international biopharma clients and data access for its personalised dosing software.
The most recent analyst rating on (GB:PYC) stock is a Hold with a £0.63 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Neutral.
The score is held back primarily by weak financial performance—persistent losses and ongoing cash burn despite a debt-free balance sheet and a 2025 revenue rebound. Technicals are supportive with price above major moving averages, but overbought signals raise near-term risk. Valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a U.K.-based mathematical modelling, data science and biostatistics company that supports the development of new therapeutics and personalised medicine solutions. It provides Modelling and Simulation and Biometrics consulting services to pharma and biotech clients, and is also developing personalised dosing software for chemotherapy and biological drugs.
Average Trading Volume: 6,608,102
Technical Sentiment Signal: Hold
Current Market Cap: £1.97M
For an in-depth examination of PYC stock, go to TipRanks’ Overview page.